DexCom

Oura is a Finnish company that specializes in the development of a smart wellness ring designed to monitor and track various biometric data related to health and well-being. The ring incorporates advanced sensors to measure key metrics such as heart rate, sleep cycles, and activity levels, providing users with insights into their physiological and behavioral responses to sleep, rest, and recovery. This data is accessible through the accompanying Oura application, which enables users to understand their overall health status and make informed lifestyle choices. Oura operates within the health and wellness industry, focusing on enhancing the user's understanding of their body and promoting better health outcomes.

Phenomix Sciences is a biotechnology company that specializes in biotech, life science, metabolomics, and genomics. It provides healthcare solutions that will enable personalized management of chronic diseases with better efficacy, fewer side effects, and lower costs. The company was founded in 2017 and headquartered in New York, United States.

Current Health Limited, founded in 2014 and based in Edinburgh, United Kingdom, specializes in developing wearable healthcare devices that monitor patients' vital signs. These devices are designed to measure key health metrics such as oxygen saturation, respiration rate, pulse rate, temperature, motion, activity, and posture, allowing for the early identification of unwell patients and timely medical intervention. The company also offers a patient monitoring platform that facilitates home-based care by enabling patients to share daily activities, report symptoms, and respond to structured questionnaires for their healthcare providers. By focusing on remote patient management, Current Health aims to reduce healthcare risks and costs while enhancing patient engagement and monitoring. Formerly known as Snap40 Limited, the company rebranded in December 2018 to better reflect its mission.

Beta Bionics is a biotechnology company focused on developing an integrated bionic pancreas system known as the iLet. This innovative device aims to alleviate the challenges and costs associated with diabetes care by providing a dual-chamber infusion pump that delivers insulin and glucagon with precision. The iLet autonomously calculates and administers the necessary doses, enabling patients to effectively manage their blood sugar levels. The system has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal options, and is compatible with Zealand Pharma’s dasiglucagon, a glucagon analogue known for its stability in a ready-to-use aqueous solution. Through this technology, Beta Bionics seeks to improve the quality of life for individuals living with diabetes.

TypeZero Technologies LLC is focused on developing inControl, a comprehensive diabetes management platform aimed at improving the quality of life for individuals with diabetes. The platform includes a smartphone-based artificial pancreas solution that automates insulin delivery, significantly reduces the risk of hypoglycemia, and enhances blood glucose control. Additionally, inControl Advice provides real-time recommendations for meal planning, basal rates, bolus calculations, and exercise, while inControl Cloud offers tools for caregivers and family members to monitor patients and analyze data for potential treatment inefficiencies. With over a decade of clinical trials and research backing its innovations, TypeZero aims to deliver personalized diabetes management solutions that empower users to effectively manage their condition. The company, established in 2013 and located in Charlottesville, Virginia, operates as a subsidiary of DexCom, Inc. since August 2018.

Nintamed is a distribution company that operates in Germany, Switzerland, and Austria, specializing in healthcare products for diabetes management. The company develops a continuous glucose monitoring system designed to track blood sugar levels, as well as pen needles for the administration of insulin. By focusing on innovative solutions for diabetes care, Nintamed aims to improve the quality of life for individuals managing this chronic condition.

SweetSpot Diabetes Care is a health data company dedicated to enhancing diabetes management through effective data utilization. The company specializes in transforming raw output from patient devices into comprehensive reports that serve researchers, healthcare providers, and patients. By facilitating data extraction and analysis, SweetSpot alleviates the challenges associated with navigating multiple interfaces, drivers, and data formats. This service allows endocrinology clinics to easily download patient device data and generate essential reports for medical professionals, equipping them with insights into blood glucose levels, patterns, and excursions. Ultimately, SweetSpot aims to empower patients in managing their diabetes through self-service data retrieval tools and improved communication between clinics and patient populations.